DOCSLIB.ORG

Application No. AU 2008290737 B2 (19) AUSTRALIAN PATENT OFFICE

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Application No. AU 2008290737 B2 (19) AUSTRALIAN PATENT OFFICE (12) STANDARD PATENT (11) Application No. AU 2008290737 B2 (19) AUSTRALIAN PATENT OFFICE (54) Title Preventing and/or treating metabolic disorders by modulating the amount of en­ terobacteria (51) International Patent Classification(s) A61K 31/702 (2006.01) A61K 35/76 (2006.01) A61K 31/7088 (2006.01) A61K 36/00 (2006.01) A61K 35/74(2006.01) A61P 3/04 (2006.01) (21) Application No: 2008290737 (22) Date of Filing: 2008.07.25 (87) WIPO No: WO09/024429 (30) Priority Data (31) Number (32) Date (33) Country 07114530.4 2007.08.17 EP (43) Publication Date: 2009.02.26 (44) Accepted Journal Date: 2013.11.14 (71) Applicant(s) Nestec S.A. (72) Inventor(s) Arigoni, Fabrizio;Philippe, David;Mace, Catherine;Darimont, Christian;Chou, Chieh Jason (74) Agent / Attorney Shelston IP, L 21 60 Margaret St, Sydney, NSW, 2000 (56) Related Art WO 2006/129092 A2 (THE UNIVERSITY OF BIRMINGHAM), 07 December 2006. LEY RE, et al, 'Human gut microbes associated with obesity,' Nature, (2006), Vol 444, pp 1022-1023 US 2006/0094672 A1 (PASQALINI et al.), 04 May 2006. US 2005/0239706 A1 (BACKHED et al.), 27 October 2005. WO 2008/116700 A1 (NESTEC S.A.), 02 October 2008 WO 2007/135141 A1 (NESTEC S.A.), 29 November 2007. BACKHEAD F, et al. 'The gut microbiodata as an environmental factor that regulates fat storage,' Proceedings of the National Academy of Sciences of USA (PNAS), (2004) Vol 101 No 44, pp 15718-15723. TURNBAUGH PJ, et al. 'An obesity-associated gut microbiome with increased capacity for energy harvest,' Nature, (2006) Vol 444, pp 1027-1031 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2009/024429 A3 26 February 2009 (26.02.2009) PCT (51) International Patent Classification: [FR/CH]; Avenue des Mousquines 27, CH-1005 Lau­ A61K31/702 (2006.01) A61K35/76 (2006.01) sanne (CH). A61K31/7088 (2006.01) A61K36/00 (2006.01) (74) Agent: MARQUARDT, Ulf; Avenue Nestle 55, A61K35/74 (2006.01) A61P3/04 (2006.01) CH-1800 Vevey (CH). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/EP2008/059809 kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, 25 July 2008 (25.07.2008) CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (25) Filing Language: English HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (26) Publication Language: English KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, (30) Priority Data: NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, 07114530.4 17 August 2007 (17.08.2007) EP SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, (71) Applicant (for all designated States except US): UG, US, UZ, VC, VN, ZA, ZM, ZW. NESTEC S.A. [CH/CH]; Avenue Nestle 55, CH-1800 (84) Designated States (unless otherwise indicated, for every Vevey (CH). kind of regional protection available): ARIPO (BW, GH, (72) Inventors; and GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (75) Inventors/Applicants (for US only): CHOU, Chieh Ja­ ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, son [CN/CH]; Avenue des Mousquines 25, CH-1005 TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, Lausanne (CH). PHILIPPE, David [FR/CH]; Avenue ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI Sainte Luce 11, CH-1003 Lausanne (CH). DARIMONT, (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, Christian [FR/CH]; Avenue Montagibert 20, CH-1005 NE, SN, TD, TG). Lausanne (CH). ARIGONI, Fabrizio [CH/CH]; Rue Maurice 2, CH-1204 Geneve (CH). MACE, Catherine Declarations under Rule 4.17: [Continued on next page] (54) Title: PREVENTING AND/OR TREATING METABOLIC DISORDERS BY MODULATING THE AMOUNT OF EN­ TEROBACTERIA (57) Abstract: The present invention relates to support­ ing weight management, weight loss and/or to the pre­ vention and/or treatment of metabolic disorders. In par­ ticular the present invention relates to preventing and/or treating metabolic disorders by modulating, in particular reducing the amount of proteobacteria and/or deferribac­ teres in the gut. One embodiment of the present inven­ tion relates to the use of a primary composition compris­ ing an agent that reduces the amount of proteobacteria, preferably gamma- proteobacteria, even more preferred enterobacteria; and/or deferribacteres in the gut for the preparation of a composition to treat or prevent metabol­ ic disorders, to support weight loss and/or to support weight management. A3 Days FIG. 2 2009/024429 WO wo 2009/024429 A31 lllllllllllll IIII lllllllllllll — as to applicant's entitlement to apply for and be granted — before the expiration of the time limit for amending the a patent (Rule 4.17(H)) claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(Hi)) (88) Date of publication of the international search report: — of inventorship (Rule 4.17 (iv)) 3 December 2009 Published: — with international search report (Art. 21(3)) WO 2009/024429 PCT/EP2008/059809 Gut flora and weight management The present invention relates to supporting weight management, weight loss and/or to the prevention and/or treatment of metabolic disorders. In particular the present invention relates 5 to preventing and/or treating metabolic disorders by modulating, in particular reducing the amount of proteobacteria and/or deferribacteres in the gut. The prevalence of obesity has grown in an alarming rate in the past 20 years. Based on the latest estimate in 2004, in the US alone, 66.3% of adults are either overweight or obese, and 10 32.2% of adults are classified as obese (Cynthia L. Ogden et al., JAMA 2006 April 5;295:1549-1555). Both genetic and environmental factors have been shown to cause positive energy balance and obesity. Obesity by itself is only a part of problems. Many other chronic diseases such as type 2 diabetes, certain cancers and cardiovascular diseases are common co­ morbidities of obesity. Collectively, all the obesity associated medical issues put a 15 tremendous amounts of pressure on health care systems in many countries. Due to the prevalence of obesity, type 2 diabetes has also become a worldwide health problem. According to an epidemiological study, the projective global prevalence for type 2 diabetic population will reach to 366 million people in 2030 (Sarah Wild et al., Diabetes Care 2004 May;27:1047-1053). Drug treatments for obesity are available but not very effective and with 20 undesirable side-effects. For the treatment of type 2 diabetes,, currently available drugs are capable of managing hyperglycemia of the patients. Still more drugs are under development to improve the safety, efficacy of the medications and convenience to use them by patients. To date, all anti-obesity and anti-diabetic drugs are designed to alter the internal metabolism of patients. Most of these drugs are required to be absorbed and delivered to target organs 25 through blood stream for their efficacy. Safety concerns of such a treatment strategy cannot be ignored. In contrast a novel treatment strategy of obesity and type 2 diabetes focussing on targets outside of human tissues is greatly desirable because the active agents are not required to enter our body, and the safety of the treatments can be improved significantly. 30 Human beings are supcrorganisms with a body composed of millions of human cells while many more bacteria live, e.g., in the colon. It has been estimated that more than 1013 to 1014 bacteria are alive in a healthy human intestine. Intestinal bacteria can be separated into 2 major divisions, firmicutes and bacteriodetes (Steven R. Gill,et al., Science 2006 June 2;312: 1355-1359; Peter J. Tumbaugh, et al., Nature 2006 Dec 21 ;444:1027-131). Together, they -2- 2013 represent at least 90% of total bacterial population in the gut. The presence of the gut Sep bacteria is a part of normal human physiology and is important for the development of gut functions (Hooper LV et al., Science. 2001 Feb 2;291 (5505):881-4; Stappenbeck TS, 24 et al., Proc Natl Acad Sci USA. 2002 Nov 26;99(24): 15451 -5), maturation of the 5 immune system (Mazmanian SK, et al., Cell. 2005 Jul 15; 122(1): 107-18), harvesting energy from dietary carbohydrates (Peter J. Tumbaugh, et al., Nature 2006 Dec 21 ;444:1027-131), harvesting essential vitamins (Backhed F, et al., Science. 2005 Mar 25;307(5717): 1915-20) and metabolizing environmental chemicals in the gut (Nicholson JK, et al., Nat Rev Microbiol. 2005 May;3(5):431-8). Recent studies further suggested 2008290737 10 that gut bacteria may be involved in fat storage (Backhed F, et al., Proc Natl Acad Sci U S A. 2004 Nov 2; 101(44): 15718-23). Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field. 15 However, until now it has never been taught or suggested to manipulate the composition of gut bacteria to treat or prevent metabolic disorders.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,018,158 B2 Onsoyen Et Al
    US0090181.58B2 (12) United States Patent (10) Patent No.: US 9,018,158 B2 Onsoyen et al. (45) Date of Patent: Apr. 28, 2015 (54) ALGINATE OLIGOMERS FOR USE IN 7,208,141 B2 * 4/2007 Montgomery .................. 424/45 OVERCOMING MULTIDRUG RESISTANCE 22:49 R: R388 al al W . aSOC ea. N BACTERA 7,671,102 B2 3/2010 Gaserod et al. 7,674,837 B2 3, 2010 G d et al. (75) Inventors: Edvar Onsoyen, Sandvika (NO); Rolf 7,758,856 B2 T/2010 it. Myrvold, Sandvika (NO); Arne Dessen, 7,776,839 B2 8/2010 Del Buono et al. Sandvika (NO); David Thomas, Cardiff 2006.8 R 38 8. Melist al. (GB); Timothy Rutland Walsh, Cardiff 2003/0022863 A1 1/2003 Stahlang et al. (GB) 2003/0224070 Al 12/2003 Sweazy et al. 2004/OO73964 A1 4/2004 Ellington et al. (73) Assignee: Algipharma AS, Sandvika (NO) 2004/0224922 A1 1 1/2004 King 2010.0068290 A1 3/2010 Ziegler et al. (*) Notice: Subject to any disclaimer, the term of this 2010/0305062 A1* 12/2010 Onsoyen et al. ................ 514/54 patent is extended or adjusted under 35 U.S.C. 154(b) by 184 days. FOREIGN PATENT DOCUMENTS DE 268865 A1 1, 1987 (21) Appl. No.: 13/376,164 EP O324720 A1 T, 1989 EP O 506,326 A2 9, 1992 (22) PCT Filed: Jun. 3, 2010 EP O590746 A1 4f1994 EP 1234584 A1 8, 2002 (86). PCT No.: PCT/GB2O1 O/OO1097 EP 1714660 A1 10, 2006 EP 1745705 A1 1, 2007 S371 (c)(1), FR T576 M 3/1968 (2), (4) Date: Jan.
    [Show full text]
  • November 2014, Version 6.0 This Document Was Created Under National Center for Emerging and Zoonotic Diseases/ Office of Infectious Diseases (NCEZID/OD)
    November 2014, Version 6.0 This document was created under National Center for Emerging and Zoonotic Diseases/ Office of Infectious Diseases (NCEZID/OD). The printed version of CDC's Infectious Diseases Laboratory Test Directory contains information that is current as of November 18st, 2014. All information contained herein is subject to change. For the most current test information, please view the CDC's Infectious Diseases Laboratory Test Directory on: http://www.cdc.gov/laboratory/specimen-submission/list.html. Test Order Acanthamoeba Molecular Detection CDC-10471 Synonym(s) Free-living ameba, parasite Pre-Approval Needed None Supplemental Information None Required Supplemental Form None Performed on Specimens From Human Acceptable Sample/ Specimen For Acanthamoeba and Balamuthia molecular detection, tissue is the preferred Type for Testing specimen type; however, these amoebae can occasionally be detected in cerebrospinal fluid (CSF). For Naegleria fowleri molecular detection, CSF is the preferred specimen type. Minimum Volume Required 500 uL Storage & Preservation of Storage and preservation is specimen specific Specimen Prior to Shipping Transport Medium Not Applicable Specimen Labeling Test subject to CLIA regulations and requires two patient identifiers on the specimen container and the test requisition. In addition to two patient identifiers (sex, date of birth, name, etc.), provide specimen type and date of collection. Shipping Instructions which Ship Monday – Thursday, overnight to avoid weekend deliveries. Ship specimen Include
    [Show full text]
  • Plesiomonas Shigelloides S000142446 Serratia Plymuthica
    0.01 Plesiomonas shigelloides S000142446 Serratia plymuthica S000016955 Serratia ficaria S000010445 Serratia entomophila S000015406 Leads to highlighted edge in Supplemental Phylogeny 1 Xenorhabdus hominickii S000735562 0.904 Xenorhabdus poinarii S000413914 0.998 0.868 Xenorhabdus griffiniae S000735553 Proteus myxofaciens S000728630 0.862 Proteus vulgaris S000004373 Proteus mirabilis S000728627 0.990 0.822 Arsenophonus nasoniae S000404964 OTU from Corby-Harris (Unpublished) #seqs-1 GQ988429 OTU from Corby-Harris et al (2007) #seqs-1 DQ980880 0.838 Providencia stuartii S000001277 Providencia rettgeri S000544654 0.999 Providencia vermicola S000544657 0.980 Isolate from Juneja and Lazzaro (2009)-EU587107 Isolate from Juneja and Lazzaro (2009)-EU587113 0.605 0.928 Isolate from Juneja and Lazzaro (2009)-EU587095 0.588 Isolate from Juneja and Lazzaro (2009)-EU587101 Providencia rustigianii S000544651 0.575 Providencia alcalifaciens S000127327 0.962 OTU XDS 099-#libs(1/0)-#seqs(1/0) OTU XYM 085-#libs(13/4)-#seqs(401/23) 0.620 OTU XDY 021-#libs(1/1)-#seqs(3/1) Providencia heimbachae S000544652 Morganella psychrotolerans S000721631 0.994 Morganella morganii S000721642 OTU ICF 062-#libs(0/1)-#seqs(0/7) Morganella morganii S000129416 0.990 Biostraticola tofi S000901778 0.783 Sodalis glossinidius S000436949 Dickeya dadantii S000570097 0.869 0.907 0.526 Brenneria rubrifaciens S000022162 0.229 Brenneria salicis S000381181 0.806 OTU SEC 066-#libs(0/1)-#seqs(0/1) Brenneria quercina S000005099 0.995 Pragia fontium S000022757 Budvicia aquatica S000020702
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0239583 A1 MURTHY Et Al
    US 2010O239583A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0239583 A1 MURTHY et al. (43) Pub. Date: Sep. 23, 2010 (54) ANTIBODIES AGAINST FLAGELLIN AND C07K I6/46 (2006.01) USES THEREOF CI2N 5/16 (2006.01) C7H 2L/04 (2006.01) (75) Inventors: KannegantiMURTHY, Stoneham, CI2N 5/3 (2006.01) MA (US); Andrew L. SALZMAN, AOIN 63/02 (2006.01) Herzliya (IL) AOIP I/00 (2006.01) A6IP3L/04 (2006.01) Correspondence Address: A6IP3L/08 (2006.01) LAHIVE & COCKFIELD, LLP A6IP3L/06 (2006.01) FLOOR 30, SUITE 3000 A6IPI3/02 (2006.01) ONE POST OFFICE SQUARE A6IP 7/00 (2006.01) BOSTON, MA 02109 (US) GOIN 33/53 (2006.01) (73) Assignee: NOTEKPHARMACEUTICALS CORPORATION, Beverly, MA (52) U.S. Cl. ................ 424/136.1; 530/388.4:530/389.5; (US) 530/387.9; 530/387.3; 530/388.15:435/340: 530/3917; 424/150.1; 424/164.1; 424/178.1; (21) Appl. No.: 12/717,351 536/23.53; 435/320.1; 435/7.1 (22) Filed: Mar. 4, 2010 (57) ABSTRACT Related U.S. Application Data The present invention provides a novel class of monoclonal (60) Provisional application No. 61/209,189, filed on Mar. antibodies which have a high affinity, broad spectrum neu 4, 2009. tralizing reactivity to flagellin from various Gram-negative O O bacteria including, but not limited to, E. coli, Salmonella, Publication Classification Serratia, Proteus, Enterobacter Citrobacter, Campylobacter (51) Int. Cl. and Pseudomonas. The present invention further provides A6K 39/395 (2006.01) methods of treating infections and diseases using anti-flagel C07K 6/12 (2006.01) lin antibodies in humans, other animals and birds.
    [Show full text]
  • Diversity and Evolution of Surface Polysaccharide Synthesis Loci in Enterobacteriales
    bioRxiv preprint doi: https://doi.org/10.1101/709832; this version posted January 28, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 1 Diversity and evolution of surface polysaccharide synthesis loci 2 in Enterobacteriales 1,2 3 1 1 3,4 Kathryn E. Holt , Florent Lassalle , Kelly L. Wyres , Ryan Wick and Rafa l J. Mostowy † 4 1) Department of Infectious Diseases, Central Clinical School, Monash University, Melbourne, Australia 2) London School of Hygiene and Tropical Medicine, London, UK 6 3) Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, UK 4) Malopolska Centre of Biotechnology, Jagiellonian University, Krakow, Poland 8 Correspondence: [email protected] † Bacterial capsules and lipopolysaccharides are diverse surface polysaccharides (SPs) that serve 10 as the frontline for interactions with the outside world. While SPs can evolve rapidly, their di- versity and evolutionary dynamics across di↵erent taxonomic scales has not been investigated in 12 detail. Here, we focused on the bacterial order Enterobacteriales (including the medically-relevant Enterobacteriaceae), to carry out comparative genomics of two SP locus synthesis regions, cps and 14 kps,using27,334genomesfrom45genera.Weidentifiedhigh-qualitycps loci in 22 genera and kps in 11 genera, around 4% of which were detected in multiple species. We found SP loci to 16 be highly dynamic genetic entities: their evolution was driven by high rates of horizontal gene transfer (HGT), both of whole loci and component genes, and relaxed purifying selection, yielding 18 large repertoires of SP diversity.
    [Show full text]
  • International Journal of Systematic and Evolutionary Microbiology (2016), 66, 5575–5599 DOI 10.1099/Ijsem.0.001485
    International Journal of Systematic and Evolutionary Microbiology (2016), 66, 5575–5599 DOI 10.1099/ijsem.0.001485 Genome-based phylogeny and taxonomy of the ‘Enterobacteriales’: proposal for Enterobacterales ord. nov. divided into the families Enterobacteriaceae, Erwiniaceae fam. nov., Pectobacteriaceae fam. nov., Yersiniaceae fam. nov., Hafniaceae fam. nov., Morganellaceae fam. nov., and Budviciaceae fam. nov. Mobolaji Adeolu,† Seema Alnajar,† Sohail Naushad and Radhey S. Gupta Correspondence Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Radhey S. Gupta L8N 3Z5, Canada [email protected] Understanding of the phylogeny and interrelationships of the genera within the order ‘Enterobacteriales’ has proven difficult using the 16S rRNA gene and other single-gene or limited multi-gene approaches. In this work, we have completed comprehensive comparative genomic analyses of the members of the order ‘Enterobacteriales’ which includes phylogenetic reconstructions based on 1548 core proteins, 53 ribosomal proteins and four multilocus sequence analysis proteins, as well as examining the overall genome similarity amongst the members of this order. The results of these analyses all support the existence of seven distinct monophyletic groups of genera within the order ‘Enterobacteriales’. In parallel, our analyses of protein sequences from the ‘Enterobacteriales’ genomes have identified numerous molecular characteristics in the forms of conserved signature insertions/deletions, which are specifically shared by the members of the identified clades and independently support their monophyly and distinctness. Many of these groupings, either in part or in whole, have been recognized in previous evolutionary studies, but have not been consistently resolved as monophyletic entities in 16S rRNA gene trees. The work presented here represents the first comprehensive, genome- scale taxonomic analysis of the entirety of the order ‘Enterobacteriales’.
    [Show full text]
  • The Evolution of Slya/Rova Transcription Factors From
    bioRxiv preprint doi: https://doi.org/10.1101/369546; this version posted December 11, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 2 3 4 5 The Evolution of SlyA/RovA Transcription Factors 6 From Repressors to Counter-Silencers in Enterobacteriaceae 7 8 9 10 W. Ryan Will1, Peter Brzovic2, Isolde Le Trong3, Ronald E. Stenkamp2,3, 11 Matthew B. Lawrenz4, Joyce E. Karlinsey5, William W. Navarre5*, Kara Main-Hester5, Virginia 12 L. Miller6, Stephen J. Libby1† and Ferric C. Fang1,5#† 13 14 15 16 Departments of 1Laboratory Medicine, 2Biochemistry, 3Biological Structure and 5Microbiology, 17 University of Washington, Seattle, WA 98195 18 4Department of Microbiology and Immunology and the Center for Predictive Medicine for 19 Biodefense and Emerging Infectious Diseases, University of Louisville School of Medicine, 20 Louisville, KY 40202 21 6Departments of Microbiology and Immunology, and Genetics, University of North Carolina 22 School of Medicine, Chapel Hill, NC 27599 23 24 25 *Present address, University of Toronto, ON, Canada M5S 1A8 26 27 #Corresponding author. E-mail address: [email protected] 28 29 †Contributed equally to this paper 30 bioRxiv preprint doi: https://doi.org/10.1101/369546; this version posted December 11, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Evolution of SlyA Transcription Factors Will, et al. 31 Abstract 32 Gene duplication and subsequent evolutionary divergence have allowed conserved proteins 33 to develop unique roles.
    [Show full text]
  • 2018 CDC Infectious Diseases Laboratory Test Directory
    CDC INFECTIOUS DISEASES LABORATORY TEST DIRECTORY May 2018, Version 8.1 This document was created under National Center for Emerging and Zoonotic Diseases/ Office of Infectious Diseases (NCEZID/OD). The printed version of CDC's Infectious Diseases Laboratory Test Directory contains information that is current as of May 4, 2018. All information contained herein is subject to change. For the most current test information, please view the 508 compliant version of the CDC's Infectious Diseases Laboratory Test Directory on: http://www.cdc.gov/laboratory/specimen- submission/list.html. Test Order Acanthamoeba Molecular Detection CDC-10471 Synonym(s) Free-living ameba, parasite Pre-Approval Needed None Supplemental Information Please provide the following information: history of present illness, exposure Required history, past medical history, treatment history, CSF results, imaging results. If images are available please upload to: http://www.cdc.gov/dpdx Supplemental Form None Performed on Specimens From Human Acceptable Sample/ Specimen For Acanthamoeba and Balamuthia molecular detection, tissue is the preferred Type for Testing specimen type; however, these amebae can occasionally be detected in cerebrospinal fluid (CSF; see 'Interference & Limitations' below). For Naegleria fowleri molecular detection, CSF is the preferred specimen type. For suspected cases of Acanthamoeba Keratitis (AK), we also accept deep corneal scraping, ocular fluid, and contact lens solution as specimen. Minimum Volume Required 0.2 g tissue: 1 mL fluids Storage & Preservation of Storage and preservation is specimen specific Specimen Prior to Shipping Transport Medium Small piece of tissue should be transported in small amount of 0.5x PBS to prevent dryness. Specimen Labeling Test subject to CLIA regulations and requires two patient identifiers on the specimen container and the test requisition.
    [Show full text]
  • CGM-18-001 Perseus Report Update Bacterial Taxonomy Final Errata
    report Update of the bacterial taxonomy in the classification lists of COGEM July 2018 COGEM Report CGM 2018-04 Patrick L.J. RÜDELSHEIM & Pascale VAN ROOIJ PERSEUS BVBA Ordering information COGEM report No CGM 2018-04 E-mail: [email protected] Phone: +31-30-274 2777 Postal address: Netherlands Commission on Genetic Modification (COGEM), P.O. Box 578, 3720 AN Bilthoven, The Netherlands Internet Download as pdf-file: http://www.cogem.net → publications → research reports When ordering this report (free of charge), please mention title and number. Advisory Committee The authors gratefully acknowledge the members of the Advisory Committee for the valuable discussions and patience. Chair: Prof. dr. J.P.M. van Putten (Chair of the Medical Veterinary subcommittee of COGEM, Utrecht University) Members: Prof. dr. J.E. Degener (Member of the Medical Veterinary subcommittee of COGEM, University Medical Centre Groningen) Prof. dr. ir. J.D. van Elsas (Member of the Agriculture subcommittee of COGEM, University of Groningen) Dr. Lisette van der Knaap (COGEM-secretariat) Astrid Schulting (COGEM-secretariat) Disclaimer This report was commissioned by COGEM. The contents of this publication are the sole responsibility of the authors and may in no way be taken to represent the views of COGEM. Dit rapport is samengesteld in opdracht van de COGEM. De meningen die in het rapport worden weergegeven, zijn die van de auteurs en weerspiegelen niet noodzakelijkerwijs de mening van de COGEM. 2 | 24 Foreword COGEM advises the Dutch government on classifications of bacteria, and publishes listings of pathogenic and non-pathogenic bacteria that are updated regularly. These lists of bacteria originate from 2011, when COGEM petitioned a research project to evaluate the classifications of bacteria in the former GMO regulation and to supplement this list with bacteria that have been classified by other governmental organizations.
    [Show full text]
  • Characterising Plant Pathogen Communities and Their Environmental Drivers at a National Scale
    Lincoln University Digital Thesis Copyright Statement The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand). This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use: you will use the copy only for the purposes of research or private study you will recognise the author's right to be identified as the author of the thesis and due acknowledgement will be made to the author where appropriate you will obtain the author's permission before publishing any material from the thesis. Characterising plant pathogen communities and their environmental drivers at a national scale A thesis submitted in partial fulfilment of the requirements for the Degree of Doctor of Philosophy at Lincoln University by Andreas Makiola Lincoln University, New Zealand 2019 General abstract Plant pathogens play a critical role for global food security, conservation of natural ecosystems and future resilience and sustainability of ecosystem services in general. Thus, it is crucial to understand the large-scale processes that shape plant pathogen communities. The recent drop in DNA sequencing costs offers, for the first time, the opportunity to study multiple plant pathogens simultaneously in their naturally occurring environment effectively at large scale. In this thesis, my aims were (1) to employ next-generation sequencing (NGS) based metabarcoding for the detection and identification of plant pathogens at the ecosystem scale in New Zealand, (2) to characterise plant pathogen communities, and (3) to determine the environmental drivers of these communities. First, I investigated the suitability of NGS for the detection, identification and quantification of plant pathogens using rust fungi as a model system.
    [Show full text]
  • Llllllllllllllllllllllllllllllll^
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization llllllllllllllllllllllllllllllll^ International Bureau (10) International Publication Number (43) International Publication Date WO 2018/073449 Al 26 April 2018 (26.04.2018) WIPO I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A 61K 38/12 (2006.01) A 61P 31/00 (2006.01) KM, ML, MR, NE, SN, TD, TG). A61K47/36 (2006.01) Published: (21) International Application Number: — with international search report (Art. 21(3)) PCT/EP2017/076927 (22) International Filing Date: 20 October 2017 (20.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1617860.0 21 October2016 (21.10.2016) GB 1714710.9 13 September 2017 (13.09.2017) GB (71) Applicant: AUGIPHARMA AS [NO/NO]; Industriveien 33, N-1337 Sandvika, N-1337 Sandvika (NO). (72) Inventors: FERGUSON, Elaine; Tissue Engineering and Reparative, Dentistry, School of Dentistry, Cardiff Univer­ sity, Heath Park Cardiff South Wales CF14 4XY (GB). THOMAS, David William; Tissue Engineering and Repar­ ative, Dentistry, School of Dentistry, Cardiff Universi­ ty, Heath Park Cardiff South Wales CF14 4XY (GB). DESSEN, Arne; Alstadhaug Terrasse 20, 3440 Royken (NO). RYE, Philip; Kalderaveien 11, 1359 Eiksmarka (NO). (74) Agent: DEHNS; St Bride's House, 10 Salisbury Square, London Greater London EC4Y 8JD (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, ΒΖ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, ΝΖ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ΖΑ, ZM, ZW.
    [Show full text]
  • Biodiversidad Bacteriana Marina: Nuevos Taxones Cultivables
    Departamento de Microbiología y Ecología Colección Española de Cultivos Tipo Doctorado en Biotecnología Biodiversidad bacteriana marina: nuevos taxones cultivables Directores de Tesis David Ruiz Arahal Mª Jesús Pujalte Domarco Mª Carmen Macián Rovira Teresa Lucena Reyes Tesis Doctoral Valencia, 2012 Dr. David Ruiz Arahal , Profesor Titular del Departamento de Microbiología y Ecología de la Universidad de Valencia, Dra. María Jesús Pujalte Domarco , Catedrática del Departamento de Microbiología y Ecología de la Universidad de Valencia, y Dra. Mª Carmen Macián Rovira , Técnico Superior de Investigación de la Colección Española de Cultivos Tipo de la Universidad de Valencia, CERTIFICAN: Que Teresa Lucena Reyes, Licenciada en Ciencias Biológicas por la Universidad de Valencia, ha realizado bajo su dirección el trabajo titulado “Biodiversidad bacteriana marina: nuevos taxones cultivables”, que presenta para optar al grado de Doctor en Ciencias Biológicas por la Universidad de Valencia. Y para que conste, en el cumplimiento de la legislación vigente, firman el presente certificado en Valencia, a. David Ruiz Arahal Mª Jesús Pujalte Domarco Mª Carmen Macián Rovira Relación de publicaciones derivadas de la presente Tesis Doctoral Lucena T , Pascual J, Garay E, Arahal DR, Macián MC, Pujalte MJ (2010) . Haliea mediterranea sp. nov., a marine gammaproteobacterium. Int J Syst Evol Microbiol 60 , 1844-8. Lucena T, Pascual J, Giordano A, Gambacorta A, Garay E, Arahal DR, Macián MC, Pujalte MJ (2010) . Euzebyella saccharophila gen. nov., sp. nov., a marine bacterium of the family Flavobacteriaceae . Int J Syst Evol Microbiol 60 , 2871-6. Lucena T, Ruvira MA, Pascual J, Garay E, Macián MC, Arahal DR, Pujalte MJ (2011) . Photobacterium aphoticum sp.
    [Show full text]